Welcome to Emergent BioSolutions Inc. fourth quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question ...
15d
Despite a dip in Q4 revenue, Emergent BioSolutions Inc (EBS) showcases significant profitability improvements and strategic positioning for future growth.
$EBS insiders have traded $EBS stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales. Here’s a ...
Zacks Investment Research on MSN15d
Emergent Biosolutions (EBS) Q4 Earnings Top EstimatesEmergent Biosolutions (EBS) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per share. This compares to loss of $0.77 per share a year ago.
GAITHERSBURG, Md. (AP) — GAITHERSBURG, Md. (AP) — Emergent Biosolutions Inc. (EBS) on Monday reported a loss of $31.3 million in its fourth quarter. The Gaithersburg, Maryland-based company said it ...
In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback